Human Metabolome Technologies Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Human Metabolome Technologies ha un patrimonio netto totale di ¥1.8B e un debito totale di ¥200.0M, che porta il suo rapporto debito/patrimonio netto a 11%. Le sue attività totali e le sue passività totali sono rispettivamente ¥2.3B e ¥480.0M. L'EBIT di Human Metabolome Technologies è ¥245.0M rendendo il suo rapporto di copertura degli interessi 122.5. Ha liquidità e investimenti a breve termine pari a ¥1.5B.

Informazioni chiave

11.0%

Rapporto debito/patrimonio netto

JP¥200.00m

Debito

Indice di copertura degli interessi	122.5x
Contanti	JP¥1.46b
Patrimonio netto	JP¥1.81b
Totale passività	JP¥480.00m
Totale attività	JP¥2.29b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture

Oct 03

Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market

Aug 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Jun 07

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

May 22

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Apr 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Mar 23

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Feb 26

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥1.8B ) di 6090 superano le sue passività a breve termine ( ¥458.0M ).

Passività a lungo termine: Le attività a breve termine di 6090 ( ¥1.8B ) superano le sue passività a lungo termine ( ¥22.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 6090 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 6090 è aumentato da 0% a 11% negli ultimi 5 anni.

Copertura del debito: Il debito di 6090 è ben coperto dal flusso di cassa operativo ( 118% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 6090 sono ben coperti dall'EBIT ( 122.5 x copertura).

Human Metabolome Technologies Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Recent updates

Less than half of directors are independent

Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture

Human Metabolome Technologies, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024

Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market

Investor sentiment deteriorates as stock falls 21%

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥15.00 per share

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies, Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Third quarter 2024 earnings released: EPS: JP¥26.54 (vs JP¥26.07 in 3Q 2023)

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Human Metabolome Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Second quarter 2024 earnings released: EPS: JP¥18.43 (vs JP¥15.41 in 2Q 2023)

Dividend of JP¥15.00 announced

Human Metabolome Technologies, Inc. to Report Q2, 2024 Results on Feb 14, 2024

First quarter 2024 earnings released: JP¥6.43 loss per share (vs JP¥2.88 loss in 1Q 2023)

Human Metabolome Technologies, Inc. to Report Q1, 2024 Final Results on Nov 10, 2023

New major risk - Earnings quality

Full year 2023 earnings released: EPS: JP¥48.27 (vs JP¥45.25 in FY 2022)

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023

Human Metabolome Technologies, Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023

Third quarter 2023 earnings released: EPS: JP¥26.07 (vs JP¥33.73 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JP¥15.41 (vs JP¥22.03 in 2Q 2022)

Human Metabolome Technologies, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Q1, 2023 Results on Nov 11, 2022

Investor sentiment improved over the past week

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Fiscal Year 2022 Results on Aug 10, 2022

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022

Insufficient new directors

Human Metabolome Technologies, Inc. to Report Q3, 2022 Results on May 13, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022

First quarter 2022 earnings released: JP¥8.14 loss per share (vs JP¥6.11 loss in 1Q 2021)

Third quarter 2021 earnings released: EPS JP¥16.96 (vs JP¥22.98 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥4.92 (vs JP¥22.98 loss in 2Q 2020)

New 90-day high: JP¥999

Human Metabolome Technologies, Inc. to Report Q2, 2021 Results on Feb 12, 2021

New 90-day low: JP¥741

New 90-day low: JP¥860

Human Metabolome Technologies, Inc. to Report Q1, 2021 Results on Nov 11, 2020

Human Metabolome Technologies, Inc. to Report Fiscal Year 2020 Results on Aug 14, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane